Agilent Technologies stock gains on digital pathology launch and raised 2026 outlook
Published on 09/08/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Agilent Technologies stock (ISIN US00846U1016) is trading near recent highs after the life-sciences company combined a stronger-than-expected fiscal third quarter with the U.S. launch of its FDA-cleared S540MD digital pathology scanner as of September 7, 2026.Robinhood For investors, the key numbers are the raised fiscal 2026 guidance and the growth in recent earnings per share.
Stock holds near recent highs
According to market data, Agilent Technologies stock recently changed hands at USD 150.86 on the New York Stock Exchange, giving the company a market capitalization of about USD 42.54 billion as of September 7, 2026.Robinhood On that trading day the shares moved between an intraday low of USD 147.78 and a high of USD 151.59, putting the closing level roughly 2.1% above the day’s low and about 0.5% below the high.Robinhood
A recent price overview shows that the prior closing price stood at USD 150.86, representing a modest gain of 0.59% on the day from the previous session when the stock closed at USD 150.86 to USD 152.53 in later trading snapshots on September 4, 2026.MarketWatch For medium-term investors, the current price range near USD 150 to USD 152 is an important reference point against which to judge the impact of new product launches and guidance changes.
Earnings beat and raised 2026 guidance
The most recent catalyst for Agilent Technologies stock comes from stronger fiscal third-quarter results and an increase in the company’s outlook for fiscal 2026, as detailed in a recent regulatory filing and earnings coverage.StockTitan For the fiscal third quarter ended July 31, 2026, Agilent reported non-GAAP earnings per share of USD 1.62, beating the consensus estimate of USD 1.49 by USD 0.13.MarketBeat That represents an earnings surprise of about 8.7% versus analyst expectations, a positive signal for the company’s profitability.
The filing shows that Agilent now expects fiscal 2026 revenue of USD 7.49 billion to USD 7.51 billion, implying reported growth of 7.8% to 8.1% and core growth of 5.8% to 6.0% compared with the prior year.StockTitan The company also raised its full-year non-GAAP EPS guidance to a range of USD 6.18 to USD 6.21, including a USD 0.06 benefit already realized from tariffs, up from a previously indicated band of USD 6.00 to USD 6.10 for fiscal 2026.StockTitan The higher guidance suggests that management sees continued demand across its analytical and diagnostics platforms despite pockets of weakness in certain instrument categories.
Earlier in fiscal 2026, Agilent reported first-quarter revenue of USD 1.80 billion, up 7.0% on a reported basis and 4.4% on a core basis versus the prior year, with non-GAAP EPS rising to USD 1.36, 4% above the previous year’s level.StockTitan These earlier results provide historical context, showing that the acceleration in earnings seen in the third quarter builds on an already improving trend rather than a one-off spike.
Analyst views and options activity
Institutional investors have been adjusting their positions in Agilent Technologies stock as the earnings recovery progresses. A recent filing shows that Allianz Asset Management GmbH increased its holdings in Agilent by 11.8% during the second quarter, lifting the position to USD 53.21 million in value.MarketBeat According to the same data, the stock currently carries an average analyst rating of “Moderate Buy” with a consensus price target of USD 170.33, implying upside of about 12.7% from the recent USD 150.86 trading level if the consensus proves accurate.MarketBeat
Analyst commentary also highlights some risks. A recent note cited in market coverage points out that Agilent’s fiscal third-quarter filing included detail describing a significant decline in liquid chromatography-mass spectrometry equipment demand in Asia, a headwind for that part of the portfolio.Robinhood This suggests that while overall guidance was raised, certain instrument segments and geographies continue to experience softness that investors must factor into their expectations.
Additional sentiment indicators come from derivatives trading. Recent news flow mentions unusually high options trading and increased volumes of put options on Agilent Technologies stock, showing that some market participants are actively hedging or speculating on near-term moves even as the fundamental picture has improved.MarketBeat For retail investors, such activity underscores that near-term volatility around product launches and earnings updates remains a possibility.
Digital pathology and spectroscopy products
A key operational theme for Agilent Technologies in late August and early September 2026 has been the expansion of its digital pathology and spectroscopy offerings. Multiple reports confirm that the company has secured FDA clearance and launched the Agilent S540MD Slide Scanner System in the United States, a whole-slide imaging digital scanner aimed at clinical pathology workflows.Robinhood The U.S. launch was announced on September 4, 2026 and is positioned as a way to help laboratories digitize tissue slides more efficiently and integrate imaging data into diagnostic decision-making.MarketBeat
In parallel, Agilent has introduced the Cary 635 FTIR spectrometer, a compact, high-performance Fourier transform infrared instrument that targets applications in materials analysis and chemical characterization.Robinhood While detailed revenue figures for these specific products are not yet available, their timing shortly after the earnings beat suggests that Agilent is leaning into high-value instrumentation niches where digital and analytical capabilities can differentiate its offerings.
Stock level and investor takeaway
As of September 7, 2026, Agilent Technologies stock is quoted at USD 150.86 on the New York Stock Exchange, with an intraday trading range between USD 147.78 and USD 151.59 and a market capitalization of about USD 42.54 billion.Robinhood For investors, the combination of an 8.7% earnings beat in the fiscal third quarter, a raised fiscal 2026 revenue and EPS outlook, and the FDA-cleared launch of the S540MD digital pathology scanner forms the core narrative behind the current valuation.
Agilent Technologies stock facts
- Company: Agilent Technologies, Inc.
- ISIN: US00846U1016
- Ticker: A
- Trading venue: NYSE
- Price (as of September 7, 2026): 150.86 USD
- Market capitalization: 42.54 billion USD (as of September 7, 2026)
- Sector / Industry: Health Care / Medical Research
- Index membership: S&P 500
